I do find it irritating that so many analysts simply look at the trajectory and current projection for V sales overseas to arrive at their conclusions. There is almost no consideration for anything else going on related to Amarin or Vascepa. Current drug trials, pending litigation, future formulations, etc.
Look, I get that it is REALLY, REALLY difficult to put a price target on some of these things that are nebulous and ill-defined (in terms of outcome for the company), but at least put some ranges, or potential outcomes attached to them.
Market Data 
Markets 
AI
